
Global R&D Pipeline
My Favorite
Hot Targets:
CCR7
Back
Total number of drugs
19
Phase II and later clinical stages
0%
Involving companies
16
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P-007 | P-007 | Monoclonal antibody | Respiratory Diseases Urogenital Diseases | C-C motif chemokine receptor 7 inhibitors | NB Health Laboratory Co. Ltd. | NB Health Laboratory Co. Ltd. | Preclinical | P-007 | detail > | ||||||||||||
| Cmp2105 | Cmp2105 | Small molecule drug | Neoplasms | C-C motif chemokine receptor 7 inhibitors | Shanghai Roche Pharmaceuticals Ltd.Paul Scherrer Institut PSI | Preclinical | Preclinical | Cmp2105 | detail > | ||||||||||||
| CCR7 (Abilita Bio) | CCR7 (Abilita Bio) | Antibody | Neoplasms Immune System Diseases Eye Diseases Hemic and Lymphatic Diseases | C-C motif chemokine receptor 7 inhibitors | Abilita Therapeutics, Inc. | Preclinical | CCR7 (Abilita Bio) | detail > | |||||||||||||
| REMD-378 | REMD-378 | Monoclonal antibody | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | C-C motif chemokine receptor 7 inhibitors | REMD Biotherapeutics, Inc. | Preclinical | REMD-378 | detail > | |||||||||||||
| JBH-492 | JBH-492 | Antibody drug conjugate (ADC) ADC | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | C-C motif chemokine receptor 7 inhibitors Tubulin inhibitors | Novartis Pharmaceuticals Corp. | Phase 1 | Cleavable linker 可裂解连接子 | Maytansinoid DM4 美登素DM4 | JBH-492 | detail > | |||||||||||
| WO2023224390 | WO2023224390 | Monoclonal antibody | Neoplasms | Kookmin University Industry-Academic Cooperation | Kookmin University Industry-Academic Cooperation | Discovery | WO2023224390 | detail > | |||||||||||||
| CN118955641 | CN118955641 | Recombinant polypeptide | Neoplasms | Sun Yat-Sen University | Sun Yat-Sen University | Discovery | CN118955641 | detail > | |||||||||||||
| TC6-D3 | TC6-D3 | Synthetic peptide | Neoplasms | C-C motif chemokine receptor 7 inhibitors | Sun Yat-Sen University | Sun Yat-Sen University | Preclinical | Preclinical | TC6-D3 | detail > | |||||||||||
| SLW-132 | SLW-132 | Small molecule drug | Neoplasms | C-C motif chemokine receptor 7 inhibitors | University of Bonn | University of Bonn | Preclinical | SLW-132 | detail > | ||||||||||||
| SLW-131 | SLW-131 | Small molecule drug | Neoplasms | C-C motif chemokine receptor 7 inhibitors | University of Bonn | University of Bonn | Preclinical | SLW-131 | detail > |
Total 19 data
1
2


